［1］Zhou NX，Huang ZQ，Zhang WZ，et al.The comprehensive analysis of the clinical classification，surgical methods and long term effects of 402 cases of hilar cholangiocarcinoma［J］.Chin J Surg，2006，44（23）：1599-1603.［周宁新，黄志强，张文智，等.402例肝门部胆管癌临床分型、手术方式与远期疗效的综合分析［J］.中华外科杂志，2006，44（23）：1599-1603.］
［2］Whittaker S，Marais R，Zhu AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma［J］．Oncogene，2010，29(36)：4989-5005.
［3］Ong SH，Hadari YR，Gotoh N，et al.Stimulation of Phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins［J］.Proc Natl Acad Sci USA，2001，98(11)：6074-6079.
［4］Yamada K，Nishida K，Hibi M，et al.Comparative FISH mapping of Gab1 and Gab2 genes in human，mouse and rat［J］.Cytogenet Cell Genet，2001，94：39-42．
［5］Dong H，Zhu G，Tamada K，et al.B7-H1，a third member of the B7 family，co-stimulates T-cell proliferation and interleukin-10 secretion［J］.Nat Med，1999，5(12)：1365-1369.
［6］Velcheti V，Schalper KA，Carvajal DE，et al.Programmed death ligand-1 expression in non-small cell lung cancer［J］.Lab Invest，2014，94(1)：107-116.
［7］Soliman H，Khalil F，Antonia S.PD-L1 expression is increased in a subset of basal type breast cancer cells［J］.PLoS One，2014，9(2)：e88557.
［8］Bae WK，Shim HJ，Choi YD，et al.Severe hypothyroidism in-duced by thyroid metastasis of cholangiocarcinoma［J］.Cancer Res Treat，2009，41(1)：56-58.
［9］Socoteanu MP，Mott F，Alpini G，et al.c-Met targeted therapy of cholangiocarcinoma［J］.World J Gastroentero，2008，14(19)：2990-2994.
［10］Sam PC，Dance M，Montagner A，et al.Signal strength dictatesphosphoinositide 3-kinase contribution to Ras／extracellulay signaI-regulated kinase 1 and 2 activation via differential Gabl／Shp2 recruitment：consequences for resistance to epidermal growthfactor receptor inhibition［J］．Mol Celt Biol，2008，28(2)：587-600．
［11］Liu L，Zhao XH，Liu JG.The expression and significance of Gab1 and SOD in cholangiocarcinoma［J］.China J Modern Med，2014，24（3）：36-40.［刘磊，赵羲和，刘金钢.Gab1与SOD在胆管癌中的表达及意义［J］.中国现代医学，2014，24（3）：36-40.］
［12］Yao X,Liu Y,Wang Y,et al.Expression and significance of Gab1 and MMP-9 in cholangiocarcinoma［J］.Modern Oncology，2013，21（01）：118-121.［姚旭，刘源，王勇，等.Gab1与MMP-9在胆管癌中的表达及意义［J］.现代肿瘤医学，2013，21（01）：118-121.］
［13］Sang HQ，Li TT，Li HY，et al.Gab1 regulates proliferation and migration through the PI3K/Akt signaling pathway in intrahepatic cholangiocarcinoma［J］.Tumour Biol，2015，36(11)：8367-8377.
［14］Furge KA Zhang，YW Vande，Woude GF，et al．Met receptor tyrosine kinase：enhanced signaling through adapter proteins［J］.Oncogene，2000，19（49）：5582-5589.
［15］Bai RP，Weng CH，Dong HJ，et al．MicroRNA-409-3p suppresses colorectal cancer invasion and metastasis partly by targeting Gab1 expression［J］.Int J Cancer，2015，137（10）：2310-2322.
［16］Matsushita H，Vesely MD，Koboldt DC，et al．Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting［J］．Nature，2012，8(482)：400-404．
［17］Chen Y，Liu P，Gao F，et al．A dimeric structure of PD-L1：functional units or evolutionary relics［J］．Protein Cell，2010，1(2)：153-160．
［18］Rozali EN，Hato SV，Robinson BW，et al.Programmed death ligand 2 in cancer-induced immune suppression［J］．Clin Dev Immunol，2012，2012：656340．
［19］Wang L，Ma Q，Chen X，et al．Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma［J］．World J Surg，2010，34(5)：1059-1065．
［20］Qing Y，Li Q，Ren T，et al．Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer［J］.Drug Des Devel Ther，2015，9：901-909.
［21］Komiya T，Madan R.PD-L1 expression in small cell lung cancer［J］.Eur J Cancer，2015，51(13)：1853-1855.
［22］David R.PD-L1 expression by circulating breast cancer cells［J］.Lancet Oncol，2015，16(7）：e321.